Clinical Trials Logo

Renal Cancer clinical trials

View clinical trials related to Renal Cancer.

Filter by:

NCT ID: NCT06239194 Not yet recruiting - Breast Cancer Clinical Trials

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Start date: May 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

NCT ID: NCT06222125 Recruiting - Renal Cancer Clinical Trials

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Start date: January 30, 2023
Phase: Phase 2
Study type: Interventional

It is a phase II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0025 in patients with advanced clear cell renal cell carcinoma (ccRCC).

NCT ID: NCT06147349 Recruiting - Renal Cancer Clinical Trials

Kidney Cancer Observational Protocol

Start date: January 27, 2010
Phase:
Study type: Observational [Patient Registry]

The aim of this observational study is to gather pre and post surgery clinical data belonging to patients who underwent radical or partial nephrectomy and to evaluate the impact of the surgery on the quality of life of the patients, as well as possible relapses within a 10 year period.

NCT ID: NCT06145139 Enrolling by invitation - Renal Cancer Clinical Trials

KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial

KIDNEY-PAGER
Start date: June 1, 2023
Phase:
Study type: Observational [Patient Registry]

The overall aim of this observational study is to confirm that circulating tumor DNA (ctDNA) detected in plasma and or urine after intended curative treatment for renal cell carcinoma (RCC) can be applied in clinical practice as a marker of subclinical residual disease and risk of recurrence.

NCT ID: NCT06116253 Recruiting - Renal Cancer Clinical Trials

Advanced Diffusion Imaging in Renal Cancer Patients

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to apply advanced diffusion imaging in a two-pronged assessment of renal mass patients: (1) characterization of lesion malignancy and subtype, and (2) prediction of renal function stability or decline following partial nephrectomy.

NCT ID: NCT06051162 Recruiting - Prostate Cancer Clinical Trials

HPI Effect in Robotic Urological Surgery on AKI

Start date: November 7, 2023
Phase: N/A
Study type: Interventional

It is a single-center randomized controlled trial that aims to figure out the effect of the hypotension prediction index (HPI) on the prevention of acute kidney injury (AKI) after robot-assisted urological surgery. The primary hypothesis is that HPI software guidance prevents postoperative AKI by reducing the duration and severity of intraoperative hypotension (IOH).

NCT ID: NCT05969496 Recruiting - Clinical trials for Renal Cell Carcinoma

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

NEOPAX
Start date: December 4, 2023
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden. A decrease in the size of the tumor thrombus can potentially lead to decrease in surgical complications, improve patient related health outcomes, and improve long term outcomes such as progression free survival and overall survival.

NCT ID: NCT05935748 Recruiting - Neoplasms Clinical Trials

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Start date: July 28, 2023
Phase: Phase 2
Study type: Interventional

The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy. The goal of the Expansion phase of the study is to evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy.

NCT ID: NCT05888532 Recruiting - Prostate Cancer Clinical Trials

64Cu-GRIP B in Patients With Advanced Malignancies

Start date: May 25, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patients with advanced cancers that has spread to nearby tissue or lymph nodes (advanced). Granzyme B (GrB) is a biomarker produced by immune cells in response to immunotherapy, which may highlight tumors that are more likely to respond to treatment. The study population is focused on genitourinary (GU) malignancies, including renal cell and urothelial cancer, two tumor types with high mutational burden and tumor infiltrating lymphocytes compared to other tumor types, and have a predictable response rate at the population level to immune checkpoint inhibitors. The information gained from this trial may allow researchers to develop future trials where 64Cu-GRIP B PET may serve as a biomarker to monitor early response to immunomodulatory therapies which are used to stimulate or suppress the immune system and may help the body fight cancer.

NCT ID: NCT05842044 Recruiting - Kidney Cancer Clinical Trials

NSAID Use After Robotic Partial Nephrectomy

No-PAIN
Start date: September 15, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see how effective non-steroidal anti-inflammatory drugs (NSAIDs) are at controlling pain without side effects in participants after robotic-assisted partial nephrectomy.